zodasiran Injection + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Homozygous Familial Hypercholesterolemia
Conditions
Homozygous Familial Hypercholesterolemia
Trial Timeline
Jun 17, 2025 → Aug 20, 2027
NCT ID
NCT07037771About zodasiran Injection + Placebo
zodasiran Injection + Placebo is a phase 3 stage product being developed by Arrowhead Pharmaceuticals for Homozygous Familial Hypercholesterolemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07037771. Target conditions include Homozygous Familial Hypercholesterolemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07037771 | Phase 3 | Recruiting |
Competing Products
20 competing products in Homozygous Familial Hypercholesterolemia